Literature DB >> 15205968

123I-beta-CIT binding and recovery from depression. A six-month follow-up study.

Teijamari Laasonen-Balk1, Heimo Viinamäki, Jyrki T Kuikka, Minna Husso-Saastamoinen, Johannes Lehtonen, Jari Tiihonen.   

Abstract

Eighteen depressive outpatients were investigated using single-photon emission computerized tomography (SPECT) with a high-affinity dopamine (DA) and serotonin transporter (SERT) specific radioligand, (123)I-labeled beta-CIT (2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane). The patients were tested at the beginning of the study and on follow-up after six months. The severity of depression was evaluated using the 17-item Hamilton Rating Scale of Depression (HRSD). Eight of the eighteen patients had an HRSD score below the median (12 points) on follow-up, and they had a significantly greater increase in (123)I-beta-CIT binding in the midbrain region compared with those patients who did not recover (ANCOVA: F = 8.12; df = 1, 14; p = 0.013). These results indicate that recovery from depression is associated with an increase in (123)I-beta-CIT binding in the midbrain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205968     DOI: 10.1007/s00406-004-0458-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  6 in total

1.  Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.

Authors:  Matthew S Milak; Ramin V Parsey; Leilani Lee; Maria A Oquendo; Doreen M Olvet; Francoise Eipper; Kevin Malone; J John Mann
Journal:  Psychiatry Res       Date:  2009-05-14       Impact factor: 3.222

2.  Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective 123I-FP-CIT SPECT imaging genetic study.

Authors:  Sabine Hellwig; Lars Frings; Annette Masuch; Werner Vach; Katharina Domschke; Claus Normann; Philipp T Meyer
Journal:  J Neural Transm (Vienna)       Date:  2018-02-23       Impact factor: 3.575

3.  Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM.

Authors:  N Herold; K Uebelhack; L Franke; H Amthauer; L Luedemann; H Bruhn; R Felix; R Uebelhack; M Plotkin
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.850

4.  Neurobiology of Chronic Stress-Related Psychiatric Disorders: Evidence from Molecular Imaging Studies.

Authors:  Margaret T Davis; Sophie E Holmes; Robert H Pietrzak; Irina Esterlis
Journal:  Chronic Stress (Thousand Oaks)       Date:  2017-06-22

5.  Dopamine dysfunction in depression: application of texture analysis to dopamine transporter single-photon emission computed tomography imaging.

Authors:  Takehiro Tamura; Genichi Sugihara; Kyoji Okita; Yohei Mukai; Hiroshi Matsuda; Hiroki Shiwaku; Shunsuke Takagi; Hiromitsu Daisaki; Ukihide Tateishi; Hidehiko Takahashi
Journal:  Transl Psychiatry       Date:  2022-08-03       Impact factor: 7.989

6.  Elevated midbrain serotonin transporter availability in mixed mania: a case report.

Authors:  Tommi Tolmunen; Mikko Joensuu; Pirjo Irmeli Saarinen; Hanna Mussalo; Pasi Ahola; Ritva Vanninen; Jyrki Kuikka; Jari Tiihonen; Johannes Lehtonen
Journal:  BMC Psychiatry       Date:  2004-09-13       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.